VIRX News and Press, Viracta Therapeutics Inc. From 03/18/22

Viracta Therapeutics Announces New Employment Inducement Grant PR Newswire SAN DIEGO , March 18, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that...

Viracta Therapeutics press release (NASDAQ:VIRX): Q4 GAAP EPS of -$0.31 beats by $0.02. Cash balance of $103.6 million as of December 31, 2021. For further details see: Viracta Therapeutics GAAP EPS of -$0.31 beats by $0.02

Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference PR Newswire SAN DIEGO , March 9, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today a...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire SAN DIEGO , Feb. 10, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, ...

IronNet IRNT +26% on multi-year pact with GCC country. Dermata Therapeutics (NASDAQ:DRMA) +28%. Twilio TWLO +19% on Q4 results. Preferred Apartment Communities APTS +16% report of takeover interest. Datadog DDOG +14% on Q4 results. Marqeta MQ +13% names...

AMC Entertainment Holdings (NYSE:AMC) +14% as preliminary Q4 revenue tops consensus. Wallbox (NYSE:WBX) +14% Uber and Wallbox to expand partnership to all of the U.S. Spire Global (NYSE:SPIR) +10% as preliminary Q4 revenue soars 111% Y/Y. ObsEva (NASDAQ:OBSV) +9%. ProQR Th...

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors First clinical trial to evaluate the safety and efficacy of Nana-val beyond lymphoma Preliminary safety and efficacy data ant...

Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference PR Newswire SAN DIEGO , Jan. 4, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today an...

Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index PR Newswire SAN DIEGO , Dec. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it h...